Allakos is committed to developing innovative therapies that transform patients’ lives

We strive to understand the needs of patients and are committed to collaborating with patients, advocacy groups, and physicians to incorporate their perspectives and needs into our development programs. Our initial focus is for the treatment of atopic dermatitis, chronic spontaneous urticaria, eosinophilic gastrointestinal diseases.

Our initial focus is on eosinophilic gastrointestinal diseases (EGIDs), a group of chronic inflammatory diseases characterized by persistent gastrointestinal symptoms as well as elevated mast cells and eosinophils in the esophagus, stomach, duodenum and/or colon.

Eosinophilic Gastrointestinal Diseases (EGIDs)

Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD)

Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD, previously referred to as eosinophilic gastroenteritis or EGE) are chronic, inflammatory diseases characterized by high levels of mast cells and eosinophils (two types of immune system cells) in the stomach and/or the duodenum. Common symptoms of these diseases include chronic abdominal pain, nausea, bloating, loss of appetite, early satiety, abdominal cramping, vomiting and diarrhea. Because many of these symptoms are non-specific, it can often take a long time for patients to be properly diagnosed with EG/EoD. It is estimated that about 50,000 patients have been diagnosed with EG/EoD in the United States, but recent evidence indicates that EG/EoD is highly underdiagnosed.

There are no approved treatments for EG/EoD, but diet modification and steroids can temporarily relieve symptoms.

Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease characterized by high levels of mast cells and eosinophils (two types of immune system cells) in the esophagus (muscular tube connecting the mouth to the stomach). Common symptoms include difficulty swallowing, food impaction (food becoming lodged in the esophagus when trying to swallow), nausea, vomiting, and abdominal pain. It is estimated that approximately 200,000 people in the United States have been diagnosed with EoE. While there are no FDA-approved treatments for EoE, esophageal dilation, diet modification, stomach acid suppressors and topical steroids can temporarily relieve symptoms.

Atopic Dermatitis

Atopic dermatitis is a chronic pruritic inflammatory condition that is characterized by dry, red, itchy patches of skin. Multiple mechanisms contribute to the disease, including epithelial barrier impairment, systemic immune dysregulation, neuroinflammation, fibrotic remodeling and dysbiosis of skin microbiota. Crosstalk between eosinophils, mast cells, and sensory neurons has been shown to drive inflammation and chronic itch in atopic dermatitis via IgE, IL-4, IL-13, IL-33, and MRGPRX2. The disease affects approximately 16.5 million (7.3%) adults in the United States (US), of which approximately 6.6 million (40%) have moderate-to-severe disease.

Chronic Urticaria

Chronic urticarias are a group of inflammatory skin diseases that are believed to be caused by the inappropriate activation of the mast cells in the skin. Symptoms of urticaria include severe itching, hives, and edema with symptoms lasting for many years. Whereas there is no identified trigger for chronic spontaneous urticaria, other chronic urticarias are caused by triggers such as physical contact with the skin (symptomatic dermographism), or passive or active increases in body temperature (cholinergic urticaria). It has been estimated that 0.5 to 1.0 percent of the U.S. population suffers from a form of chronic urticaria. First-line treatment consists of H1 antihistamine medication, however a significant number of patients do not receive adequate benefit even at four times the labeled dose.

EGID Resources

In an effort to provide patients and their families with access to valuable resources for EGIDs, we have compiled the following links. These links will take you away from the Allakos website, but will connect you with other sources of information that may be useful.


American Partnership for Eosinophilic Disorders (APFED)

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGiR)

North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN)

Campaign Urging Research for Eosinophilic Disease (CURED)